Trial reportPloS one2014
Comparison of "Live High-Train Low" in normobaric versus hypobaric hypoxia.
Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 64 citations in OpenAlex.
- Endurance, aerobic high-intensity, and repeated sprint cycling performance is unaffected by normobaric "Live High-Train Low": a double-blind placebo-controlled cross-over study.European journal of applied physiology · 2017Trial
- Trial
- Prooxidant/Antioxidant Balance in Hypoxia: A Cross-Over Study on Normobaric vs. Hypobaric "Live High-Train Low".PloS one · 2015Trial
- Time-dependent changes in aerobic capacity of acute sub-high altitude exposure in elite youth endurance athletes.Frontiers in physiology · 2026Article
- Intelligent monitoring and individualized strategies for preventing altitude sickness during altitude training.Frontiers in physiology · 2025Review
- Strength and muscle mass development after a resistance-training period at terrestrial and normobaric intermittent hypoxia.Pflugers Archiv : European journal of physiology · 2024Article
- Four-week experimental plus 1-week taper period using live high train low does not alter muscle glycogen content.European journal of applied physiology · 2024Article
- Article
- A study of survival strategies for improving acclimatization of lowlanders at high-altitude.Heliyon · 2023Review
- Both Hypoxia and Hypobaria Impair Baroreflex Sensitivity but through Different Mechanisms.International journal of sports medicine · 2023Article
- Intermittent Hypoxia Conditioning: A Potential Multi-Organ Protective Therapeutic Strategy.International journal of medical sciences · 2023Review
- Independent effects of acute normobaric hypoxia and hypobaric hypoxia on human physiology.Scientific reports · 2022Article
- Altitude and Erythropoietin: Comparative Evaluation of Their Impact on Key Parameters of the Athlete Biological Passport: A Review.Frontiers in sports and active living · 2022Review
- Validity of Peripheral Oxygen Saturation Measurements with the Garmin FēnixSensors (Basel, Switzerland) · 2021Article
- Similar Supine Heart Rate Variability Changes During 24-h Exposure to Normobaric vs. Hypobaric Hypoxia.Frontiers in neuroscience · 2021Article
- Intermittent Hypoxia Exposure Helps to Restore the Reduced Hemoglobin Concentration During Intense Exercise Training in Trained Swimmers.Frontiers in physiology · 2021Article
- The Use of the SpOFrontiers in physiology · 2020Article
- Hematological status and endurance performance predictors after low altitude training supported by normobaric hypoxia: a double-blind, placebo controlled study.Biology of sport · 2019Article
- Contemporary Periodization of Altitude Training for Elite Endurance Athletes: A Narrative Review.Sports medicine (Auckland, N.Z.) · 2019Review
- The Effects of Altitude Training on Erythropoietic Response and Hematological Variables in Adult Athletes: A Narrative Review.Frontiers in physiology · 2018Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the changes in both performance and selected physiological parameters following a Live High-Train Low (LHTL) altitude camp in either normobaric hypoxia (NH) or hypobaric hypoxia (HH) replicating current "real" practices of endurance athletes. Well-trained triathletes were split into two groups (NH, n = 14 and HH, n = 13) and completed an 18-d LHTL camp during which they trained at 1100-1200 m and resided at an altitude of 2250 m (PiO2 = 121.7±1.2 vs. 121.4±0.9 mmHg) under either NH (hypoxic chamber; FiO2 15.8±0.8%) or HH (real altitude; barometric pressure 580±23 mmHg) conditions. Oxygen saturations (SpO2) were recorded continuously daily overnight. PiO2 and training loads were matched daily. Before (Pre-) and 1 day after (Post-) LHTL, blood samples, VO2max, and total haemoglobin mass (Hb(mass)) were measured. A 3-km running test was performed near sea level twice before, and 1, 7, and 21 days following LHTL. During LHTL, hypoxic exposure was lower for the NH group than for the HH group (220 vs. 300 h; P<0.001). Night SpO2 was higher (92.1±0.3 vs. 90.9±0.3%, P<0.001), and breathing frequency was lower in the NH group compared with the HH group (13.9±2.1 vs. 15.5±1.5 breath.min(-1), P<0.05). Immediately following LHTL, similar increases in VO2max (6.1±6.8 vs. 5.2±4.8%) and Hb(mass) (2.6±1.9 vs. 3.4±2.1%) were observed in NH and HH groups, respectively, while 3-km performance was not improved. However, 21 days following the LHTL intervention, 3-km run time was significantly faster in the HH (3.3±3.6%; P<0.05) versus the NH (1.2±2.9%; ns) group. In conclusion, the greater degree of race performance enhancement by day 21 after an 18-d LHTL camp in the HH group was likely induced by a larger hypoxic dose. However, one cannot rule out other factors including differences in sleeping desaturations and breathing patterns, thus suggesting higher hypoxic stimuli in the HH group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.